Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | Peters, S | |
dc.contributor.author | Bubendorf, L | |
dc.contributor.author | Dafni, U | |
dc.contributor.author | Kerr, K | |
dc.contributor.author | Hager, H | |
dc.contributor.author | Soltermann, A | |
dc.contributor.author | O'Byrne, K | |
dc.contributor.author | Dooms, C | |
dc.contributor.author | Sejda, A | |
dc.contributor.author | Hernández-Losa, J | |
dc.contributor.author | Marchetti, A | |
dc.contributor.author | Savic, S | |
dc.contributor.author | Tan, Q | |
dc.contributor.author | Thunnissen, E | |
dc.contributor.author | Speel, E | |
dc.contributor.author | Cheney, R | |
dc.contributor.author | Nonaka, Daisuke | |
dc.contributor.author | de Jong, J | |
dc.contributor.author | Martorell, M | |
dc.contributor.author | Letovanec, I | |
dc.contributor.author | Rosell, R | |
dc.contributor.author | Stahel, R | |
dc.date.accessioned | 2014-08-05T14:04:36Z | |
dc.date.available | 2014-08-05T14:04:36Z | |
dc.date.issued | 2014-07-28 | |
dc.identifier.citation | Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. 2014: J Clin Oncol | en |
dc.identifier.issn | 1527-7755 | |
dc.identifier.pmid | 25071109 | |
dc.identifier.doi | 10.1200/JCO.2013.54.5921 | |
dc.identifier.uri | http://hdl.handle.net/10541/324239 | |
dc.description.abstract | The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en |
dc.title | Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. | en |
dc.type | Article | en |
dc.contributor.department | Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
html.description.abstract | The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. |